Normal variants and pitfalls in whole-body PET imaging with 18F FDG

Applied Radiology

Volumn 35, Issue 6, 2006, Pages 16-30

  Bogsrud, Trond Velde ^a   Lowe, Val J ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ARTICLE; ARTIFACT; BONE EXAMINATION; BONE MARROW; BRAIN; BREAST; BROWN ADIPOSE TISSUE; BURSITIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG DISTRIBUTION; DRUG UPTAKE; FRACTURE HEALING; GENITAL SYSTEM EXAMINATION; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; LUNG; LYMPH NODE METASTASIS; MEDIASTINUM; MUSCLE METASTASIS; NASOPHARYNX; NEUROIMAGING; NORMAL VALUE; OSTEOARTHRITIS; PARANASAL SINUS; POSITRON EMISSION TOMOGRAPHY; SKIN; SPINAL CORD; THYMUS; THYROID GLAND; TUMOR; UROLOGIC EXAMINATION; WHOLE BODY SCINTISCANNING;

EID: 33745308111     PISSN: 01609963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Townsend D. A future for PET/CT. In: Czernin J, Dahlbom M, Ratib O, Schiepers C, eds. Atlas of PET/CT Imaging in Oncology. New York, NY: Springer-Verlag; 2004:12-20.
2. Czemin J, Yap C. From FDG-PET to FDG-PET/CT. In: Czemin J, Dahlbom M, Ratib O, Schlepers C, eds. Atlas of PET/CT Imaging in Oncology. New York NY: Springer-Verlag; 2004:46-53.
3. Oehr P. Metabolism and transport of glucose and FDG. In: Ruhlmann J, Oehr P, Blersack HJ, eds. PET' in Oncology. Basics and clinical applications. Berlin, Germany: Springer-Verlag; 1999:43-57.
4. Kowalsky RJ, Falen SW, eds. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine. 2nd ed. Washington DC: American Pharmacists Association. 2004.
5. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32:47-59.
6. Shreve PD, Bui CDH. Normal variants in FDG PET imaging. In: Wahl RL, ed. Principles and Practice of Positron Emission Tomography. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:111-136.
7. Hamblen SM, Lowe VJ. Clinical 18F-FDG oncology patient preparation techniques. J Nucl Med Technol. 2003;31:3-7.
8. Cook GJR. Artifacts and normal variants in PET imaging. In: Valk PE, Bailey DL, Townsend DW, Maisey MN, ads. Positron Emission Tomography. Basic Science and Clinical Practice. London, UK: Springer-Verlag; 2003:495-505.
9. Kipper MS, Tartar M. Clinical Atlas of PET. With Imaging Correlation. Philadelphia, PA: W. B. Saunders; 2004.
10. Seltzer M, Schiepers C. Normal pattern and common pitfalls of FDG-PET image Interpretation. In: Czemin J, Dahlbom M, Ratib O, Schiepers C, eds. Atlas of PET/CT Imaging In Oncology. New York, NY: Springer-Verlag; 2004:54-59.
11. Czemin J, Dahlbom M, Ratib O, Schiepers C, eds. Atlas of PET/CT Imaging in Oncology. New York NY: Springer-Verlag; 2004.
12. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation. Semin Nucl Med. 1996;26:308-314.
13. Nakamoto Y, Tatsumi M, Hammoud D, et al. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology. 2005; 234:879-885.
14. Torizuka T, Zasadny KR, Wahl RL. Diabetes Decreases FDG accumulation in primary lung cancer. Clin Positron Imaging. 1999;2:281-287.
15. Hany TF, Gharehpapagh E, Kamel EM, et al. Brown adipose tissue: A factor to consider in symmetric tracer uptake in the neck and upper chest region. Eur J Nucl Mol Imaging. 2002;29:1393-1398.
16. Cohade C, Osman M, Pannu HK, Wahl RL. Uptake In the supraclavicular area fat ("USA-FAT"): Description on 18F-FDG PET/CT. J Nucl Med. 2003;44:170-176.
17. Truong MT, Erasmus JJ, Munden RF, et al. Focal FDG uptake in mediastinal brown fat mimicking malignancy'. A potential pitfall resolved on PET/CT. AJR Am J Roentgenol. 2004;183:1127-1132.
18. Weber WA. Brown adipose tissue and nuclear medicine imaging. J Nucl Med. 2004;45:1101-1103.
19. Tatsumi M, Engles JM, Ishimori T, et al. Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med. 2004;45:1189-1193.
20. Van Heertum RL, Tikofsky RS. Brain tumors, other diseases, and activation. In: Van Heertum RL, Tikofsky RS. Functional Cerebral SPECT and PET Imaging. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:275-312.
21. Lowe VJ, Stack BC. PET imaging in head and neck cancer. In: Valk PE, Bailey DL, Townsend DW, Maisey MN, eds. Positron Emission Tomography: Basic Science and Clinical Practice. London, UK: Springer-Verlag; 2003:535-546.
22. Yasuda S, Shohtsu A, Ide M, et al. Chronic thyroiditis: Diffuse uptake of FDG at PET. Radiology. 1998;207:775-778.
23. Glanoukakis AG, Karam M, Cheema A, Cooper JA. Autonomous thyroid nodules visualized by positron emission tomography with 18F-fluorode-oxyglucose: A case report and review of the literature. Thyroid. 2003;13:395-399.
24. Boemer AR, Voth E, Theissen P, et al. Glucose metabolism of the thyroid In Graves'disease measured by F-18-fluoro-deoxyglucose positron emission tomography. Thyroid. 1998;8:765-772.
25. Boemer AR, Voth E, Theissen P, et al. Glucose metabolism of the thyroid in autonomous goiter measured by F-18-FDG-PE. Exp Clin Endocrinol Diabetes. 2000;108:191-196.
26. Bogsrud TV, Karantanis D, Nathan MA, et al. Focal high uptake in the thyroid gland as an incidental finding on 18F-FDG PET. Thyroid. 2004;14:760, abstract 240.
27. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery. 2001;130:941-946.
28. Van den Bruel A, Maes A, De Potter T, et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab. 2002;87:1517-1520.
29. Kang KW, Kim SK, Kang HS, et al. Prevalence and risk of cancer of focal thyroid incidentaloma idenfied by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab. 2003;88:4100-4104.
30. Van den Bruel A, Maes A, De Potter T, et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab. 2002;87:1517-1520.
31. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery. 1993;114:728-735.
32. Gianoukakis AG, Karam M, Cheema A, Cooper JA. Autonomous thyroid nodules visualized by positron emission tomography with 18F-fluorode-oxyglucose: A case report and review of the literature. Thyroid. 2003;13:395-399.
33. McAdams HP, Erasums JJ, Patz EF, Goodman PC, Coleman RE. Evaluation of patients with round atelectasis using 2-[18F]-fluoro-2-deoxy-D-glucose PET. J Comput Assist Tomogr 1998;22:601-604.
34. Kavanagh PV, Stevenson AW, Chen MY, Clark PB. Nonneoplastic diseases in the chest showing increased activity on FDG PET. AJR Am J Roentgenol. 2004;183:1133-1141.
35. de Groot M, Meeuwis AP, Kok PJ, et al. Influence of blood glucose level, age and fasting period on nonpathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging. 2005;32:98-101.
36. Pandit-Taskar N, Schöder H, Gonen M, et al. Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. AJR Am J Roentgenol. 2004;183:1143-1147.
37. Neurath MF, Vehling D, Schunk K, et al. Noninvasive assessment of Crohn's disease activity. A comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol. 2002;97:1978-1985.
38. Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696-703.
39. Zhuang H, Sam JW, Chacko TK, et al. Rapid normalization of osseous FDG uptake following traumatic or surgical fractures. Eur J Nucl Med Mol Imaging. 2003;30:1096-1103.
40. Shon IH, Fogelman I. F-18 FDG positron emission tomography and benign fractures. Clin Nucl Med. 2003;28:171-175.
41. Schmitz A, Risse JH, Textor J, et al. FDG-PET findings of vertebral compression fractures in osteoporosis: Preliminary results. Osteoporos Int. 2002; 13:755-761.
42. Belhocine T, Blockmans D, Hustinx R, et al. Imaging of large vessel vasculitis with (18)FDG PET: Illusion or reality? A critical review of the literature data. Eur J Nucl Med Mol Imaging. 2003;30: 1305-1313.
43. Stumpe KD, Dazzi H, Schaffner A, von Schufthess GK. Infection imaging using whole-body FDG-PET. Eur. J Nucl Med. 2000;27:822-832.
44. Osman MM, Cohade C, Nakamoto Y, Wahl RL. Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT. Eur J Nucl Med Mol Imaging. 2003; 30:603-606.
45. Nehmeh SA, Erdi YE, Rosenzweig KE, et al. Reduction of respiratory motion artifacts in PET imaging of lung cancer by respiratory correlated dynamic PET: Methodology and comparison with respiratory gated PET. J Nucl Med. 2003;44:1644-1648.
46. Yau YY, Chan WS, Tam YM, et al. Application of Intravenous contrast in PET/CT: Does it really introduce significant attenuation correction error? J Nucl Med. 2005;46:283-291.